TapewireFind a company

person · Reporting owner

Estepan Ian Michael

Disclosed activity across 1 company

Tapewire entity
61124
SEC CIK
0001836254

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
Sarepta Therapeutics, Inc.SRPT · Entity 4426Chief Operating OfficerSeptember 04, 2026September 09, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Sarepta Therapeutics, Inc.

Report date September 04, 2026 · Filed September 09, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect177,184 Reported balance After 2026-09-04 transaction · row 1
1 source row

Row 1 · 2026-09-04 · Tax withholding · Disposed 24,799 · Balance 177,184

F1: Shares were withheld by the Company to satisfy tax withholding obligations related to vesting of restricted stock units granted on September 3, 2025.

Filing footnotes · ownership attribution and instrument terms

F1: Shares were withheld by the Company to satisfy tax withholding obligations related to vesting of restricted stock units granted on September 3, 2025.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
September 04, 2026 Filed Sep 9, 2026 00:03 UTC Sarepta Therapeutics, Inc. SRPT · Entity 4426 Tax withholdingCommon Stock 24,799 $22.22 $551,033.78
Disclosure

SEC source: 0001193125-26-385544 · ownership.xml · nonDerivative · entry 1

Estepan Ian Michael · CIK 0001836254 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 177,184

F1 · kind: Shares were withheld by the Company to satisfy tax withholding obligations related to vesting of restricted stock units granted on September 3, 2025.

Read SEC document
March 11, 2026 Filed Mar 14, 2026 00:09 UTC Sarepta Therapeutics, Inc. SRPT · Entity 4426 Tax withholdingCommon Stock 1,097 $17.03 $18,681.91
Disclosure

SEC source: 0001193125-26-106710 · ownership.xml · nonDerivative · entry 1

Estepan Ian Michael · CIK 0001836254 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 201,983

F1 · kind: Shares were withheld by the Company to satisfy tax withholding obligations related to vesting of restricted stock units granted on March 10, 2025.

Read SEC document
March 09, 2026 Filed Mar 12, 2026 00:01 UTC Sarepta Therapeutics, Inc. SRPT · Entity 4426 Tax withholdingCommon Stock 583 $16.95 $9,881.85
Disclosure

SEC source: 0001193125-26-102701 · ownership.xml · nonDerivative · entry 2

Estepan Ian Michael · CIK 0001836254 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 203,080

F2 · kind: Shares were withheld by the Company to satisfy tax withholding obligations related to vesting of restricted stock units granted on March 6, 2023.

Read SEC document
March 09, 2026 Filed Mar 12, 2026 00:01 UTC Sarepta Therapeutics, Inc. SRPT · Entity 4426 Tax withholdingCommon Stock 1,036 $16.95 $17,560.20
Disclosure

SEC source: 0001193125-26-102701 · ownership.xml · nonDerivative · entry 1

Estepan Ian Michael · CIK 0001836254 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 203,663

F1 · kind: Shares were withheld by the Company to satisfy tax withholding obligations related to vesting of restricted stock units granted on March 7, 2022.

Read SEC document
March 02, 2026 Filed Mar 4, 2026 01:04 UTC Sarepta Therapeutics, Inc. SRPT · Entity 4426 Tax withholdingCommon Stock 875 $16.20 $14,175.00
Disclosure

SEC source: 0001193125-26-089432 · ownership.xml · nonDerivative · entry 3

Estepan Ian Michael · CIK 0001836254 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 204,699

F3 · kind: Shares were withheld by the Company to satisfy tax withholding obligations related to vesting of restricted stock units granted on March 1, 2024.

Read SEC document
March 02, 2026 Filed Mar 4, 2026 01:04 UTC Sarepta Therapeutics, Inc. SRPT · Entity 4426 Tax withholdingCommon Stock 3,301 $16.20 $53,476.20
Disclosure

SEC source: 0001193125-26-089432 · ownership.xml · nonDerivative · entry 2

Estepan Ian Michael · CIK 0001836254 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 205,574

F2 · kind: Shares were withheld by the Company to satisfy tax withholding obligations related to vesting of a PSU award granted on March 1, 2024.

Read SEC document
March 01, 2026 Filed Mar 4, 2026 01:04 UTC Sarepta Therapeutics, Inc. SRPT · Entity 4426 Exercise / conversionPerformance Stock Units · Derivative 8,125 $0.00 $0.00
Disclosure

SEC source: 0001193125-26-089432 · ownership.xml · derivative · entry 4

Estepan Ian Michael · CIK 0001836254 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 8,125 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Represents the number of shares previously earned under a PSU award granted to the Reporting Person on March 1, 2024. The number of shares earned is based on the Compensation Committee's determination of the Company's achievement of the prescribed milestones under the terms of the PSU award. The shares vested on March 1, 2026.

F1 · derivative.exercise_date: Represents the number of shares previously earned under a PSU award granted to the Reporting Person on March 1, 2024. The number of shares earned is based on the Compensation Committee's determination of the Company's achievement of the prescribed milestones under the terms of the PSU award. The shares vested on March 1, 2026.

F1 · derivative.expiration_date: Represents the number of shares previously earned under a PSU award granted to the Reporting Person on March 1, 2024. The number of shares earned is based on the Compensation Committee's determination of the Company's achievement of the prescribed milestones under the terms of the PSU award. The shares vested on March 1, 2026.

Read SEC document
March 01, 2026 Filed Mar 4, 2026 01:04 UTC Sarepta Therapeutics, Inc. SRPT · Entity 4426 Exercise / conversionCommon Stock 8,125 Not disclosed Not disclosed
Disclosure

SEC source: 0001193125-26-089432 · ownership.xml · nonDerivative · entry 1

Estepan Ian Michael · CIK 0001836254 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 208,875

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Represents the number of shares previously earned under a PSU award granted to the Reporting Person on March 1, 2024. The number of shares earned is based on the Compensation Committee's determination of the Company's achievement of the prescribed milestones under the terms of the PSU award. The shares vested on March 1, 2026.

Read SEC document
February 26, 2026 Filed Mar 2, 2026 13:00 UTC Sarepta Therapeutics, Inc. SRPT · Entity 4426 Exercise / conversionStock Option (right to buy) · Derivative 5,381 $0.00 Strike: $13.71 $0.00
Disclosure

SEC source: 0001193125-26-084265 · ownership.xml · derivative · entry 4

Estepan Ian Michael · CIK 0001836254 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 5,381 shares

Expires 2026-02-28

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
February 26, 2026 Filed Mar 2, 2026 13:00 UTC Sarepta Therapeutics, Inc. SRPT · Entity 4426 Exercise / conversionStock Option (right to buy) · Derivative 2,069 $0.00 Strike: $13.71 $0.00
Disclosure

SEC source: 0001193125-26-084265 · ownership.xml · derivative · entry 3

Estepan Ian Michael · CIK 0001836254 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 2,069 shares

Expires 2026-02-28

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
February 26, 2026 Filed Mar 2, 2026 13:00 UTC Sarepta Therapeutics, Inc. SRPT · Entity 4426 Exercise / conversionCommon Stock 5,381 $13.71 $73,773.51
Disclosure

SEC source: 0001193125-26-084265 · ownership.xml · nonDerivative · entry 2

Estepan Ian Michael · CIK 0001836254 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 200,750

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Represents shares held by the Reporting Person after the exercise of a stock option.

Read SEC document
February 26, 2026 Filed Mar 2, 2026 13:00 UTC Sarepta Therapeutics, Inc. SRPT · Entity 4426 Exercise / conversionCommon Stock 2,069 $13.71 $28,365.99
Disclosure

SEC source: 0001193125-26-084265 · ownership.xml · nonDerivative · entry 1

Estepan Ian Michael · CIK 0001836254 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 195,369

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Represents shares held by the Reporting Person after the exercise of a stock option.

Read SEC document
February 25, 2026 Filed Feb 28, 2026 01:05 UTC Sarepta Therapeutics, Inc. SRPT · Entity 4426 GrantPerformance Stock Units · Derivative 1,875 Not disclosed Not disclosed
Disclosure

SEC source: 0001193125-26-083674 · ownership.xml · derivative · entry 1

Estepan Ian Michael · CIK 0001836254 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,125

Underlying: Common Stock · 1,875 shares

Expires not disclosed

F1 · derivative.exercise_price: Represents the number of shares earned under a PSU award granted to the Reporting Person on March 1, 2024. The number of shares earned is based on the Compensation Committee's determination of the Company's achievement of the prescribed milestones under the terms of the PSU award. The earned PSUs will vest on March 1, 2026, subject to the Reporting Person continuing to provide service to the Company through such vesting date.

F1 · price: Represents the number of shares earned under a PSU award granted to the Reporting Person on March 1, 2024. The number of shares earned is based on the Compensation Committee's determination of the Company's achievement of the prescribed milestones under the terms of the PSU award. The earned PSUs will vest on March 1, 2026, subject to the Reporting Person continuing to provide service to the Company through such vesting date.

F1 · derivative.exercise_date: Represents the number of shares earned under a PSU award granted to the Reporting Person on March 1, 2024. The number of shares earned is based on the Compensation Committee's determination of the Company's achievement of the prescribed milestones under the terms of the PSU award. The earned PSUs will vest on March 1, 2026, subject to the Reporting Person continuing to provide service to the Company through such vesting date.

F1 · derivative.expiration_date: Represents the number of shares earned under a PSU award granted to the Reporting Person on March 1, 2024. The number of shares earned is based on the Compensation Committee's determination of the Company's achievement of the prescribed milestones under the terms of the PSU award. The earned PSUs will vest on March 1, 2026, subject to the Reporting Person continuing to provide service to the Company through such vesting date.

Read SEC document
December 16, 2025 Filed Dec 19, 2025 01:05 UTC Sarepta Therapeutics, Inc. SRPT · Entity 4426 SaleCommon Stock 13,187 $22.31 $294,201.97
Disclosure

SEC source: 0001193125-25-325383 · ownership.xml · nonDerivative · entry 1

Estepan Ian Michael · CIK 0001836254 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 193,300

F1 · shares: Represents a sale of shares of common stock to generate cash for the payment of taxes due as a result of the vesting of certain restricted stock unit awards.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.35 to 22.29, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

Read SEC document
September 03, 2025 Filed Sep 6, 2025 01:30 UTC Sarepta Therapeutics, Inc. SRPT · Entity 4426 GrantCommon Stock 50,000 $0.00 $0.00
Disclosure

SEC source: 0001193125-25-197423 · ownership.xml · nonDerivative · entry 2

Estepan Ian Michael · CIK 0001836254 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 206,487

F2 · shares: The Reporting Person was granted restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock. 100% of the RSUs will vest on September 3, 2028, subject to the Reporting Person's continued service to the Company and only if certain performance criteria has been deemed achieved by the Compensation Committee of the Board.

Read SEC document
September 03, 2025 Filed Sep 6, 2025 01:30 UTC Sarepta Therapeutics, Inc. SRPT · Entity 4426 GrantCommon Stock 93,875 $0.00 $0.00
Disclosure

SEC source: 0001193125-25-197423 · ownership.xml · nonDerivative · entry 1

Estepan Ian Michael · CIK 0001836254 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 156,487

F1 · shares: The Reporting Person was granted restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock. 50% of the RSUs will vest on September 3, 2026, and the remaining 50% will vest on September 3, 2027, subject to the Reporting Person's continued service to the Company.

Read SEC document
August 05, 2025 Filed Aug 7, 2025 00:02 UTC Sarepta Therapeutics, Inc. SRPT · Entity 4426 GrantPerformance Stock Units · Derivative 6,250 $0.00 $0.00
Disclosure

SEC source: 0000950170-25-104398 · ownership.xml · derivative · entry 1

Estepan Ian Michael · CIK 0001836254 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,250

Underlying: Common Stock · 6,250 shares

Expires not disclosed

F1 · derivative.exercise_price: Represents the number of shares earned under a PSU award granted to the Reporting Person on March 1, 2024. The number of shares earned is based on the Compensation Committee's determination of the Company's achievement of the prescribed milestones under the terms of the PSU award. The earned PSUs will vest on March 1, 2026, subject to the Reporting Person continuing to provide service to the Company through such vesting date.

F1 · derivative.exercise_date: Represents the number of shares earned under a PSU award granted to the Reporting Person on March 1, 2024. The number of shares earned is based on the Compensation Committee's determination of the Company's achievement of the prescribed milestones under the terms of the PSU award. The earned PSUs will vest on March 1, 2026, subject to the Reporting Person continuing to provide service to the Company through such vesting date.

F1 · derivative.expiration_date: Represents the number of shares earned under a PSU award granted to the Reporting Person on March 1, 2024. The number of shares earned is based on the Compensation Committee's determination of the Company's achievement of the prescribed milestones under the terms of the PSU award. The earned PSUs will vest on March 1, 2026, subject to the Reporting Person continuing to provide service to the Company through such vesting date.

Read SEC document
March 10, 2025 Filed Mar 12, 2025 00:00 UTC Sarepta Therapeutics, Inc. SRPT · Entity 4426 GrantStock Options (right to buy) · Derivative 16,644 $0.00 Strike: $99.69 $0.00
Disclosure

SEC source: 0000950170-25-037519 · ownership.xml · derivative · entry 6

Estepan Ian Michael · CIK 0001836254 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,644

Underlying: Common Stock · 16,644 shares

Expires 2035-03-10

F5 · derivative.exercise_date: Represents the date upon which the first 25% of the option granted vests. 1/48th of the total granted option vests and become exercisable on each monthly anniversary thereafter.

Read SEC document
March 10, 2025 Filed Mar 12, 2025 00:00 UTC Sarepta Therapeutics, Inc. SRPT · Entity 4426 GrantCommon Stock 8,276 Not disclosed Not disclosed
Disclosure

SEC source: 0000950170-25-037519 · ownership.xml · nonDerivative · entry 4

Estepan Ian Michael · CIK 0001836254 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 62,612

F4 · price: The Reporting Person was granted restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock. 25% of the shares of common stock underlying each RSU will vest on the first anniversary of the grant date, and additional 25% will vest on each anniversary of the Grant Date thereafter, such that the RSUs will be fully vested on the fourth anniversary of the grant date.

Read SEC document
March 10, 2025 Filed Mar 12, 2025 00:00 UTC Sarepta Therapeutics, Inc. SRPT · Entity 4426 Tax withholdingCommon Stock 2,890 $100.13 $289,375.70
Disclosure

SEC source: 0000950170-25-037519 · ownership.xml · nonDerivative · entry 3

Estepan Ian Michael · CIK 0001836254 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 54,336

F3 · shares: Shares were sold by the Company to satisfy tax withholding obligations related to vesting of PSUs granted on March 7, 2022.

Read SEC document
March 10, 2025 Filed Mar 12, 2025 00:00 UTC Sarepta Therapeutics, Inc. SRPT · Entity 4426 Tax withholdingCommon Stock 1,051 $100.13 $105,236.63
Disclosure

SEC source: 0000950170-25-037519 · ownership.xml · nonDerivative · entry 2

Estepan Ian Michael · CIK 0001836254 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 57,226

F2 · shares: Shares were sold by the Company to satisfy tax withholding obligations related to vesting of restricted stock units granted on March 7, 2022.

Read SEC document
March 07, 2025 Filed Mar 11, 2025 00:00 UTC Sarepta Therapeutics, Inc. SRPT · Entity 4426 Tax withholdingCommon Stock 9,094 $103.70 $943,047.80
Disclosure

SEC source: 0000950170-25-036695 · ownership.xml · nonDerivative · entry 3

Estepan Ian Michael · CIK 0001836254 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 52,777

F3 · shares: Shares were sold by the Company to satisfy tax withholding obligations related to vesting of PSUs granted on March 6, 2023.

Read SEC document
March 07, 2025 Filed Mar 11, 2025 00:00 UTC Sarepta Therapeutics, Inc. SRPT · Entity 4426 Tax withholdingCommon Stock 585 $103.70 $60,664.50
Disclosure

SEC source: 0000950170-25-036695 · ownership.xml · nonDerivative · entry 2

Estepan Ian Michael · CIK 0001836254 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 61,871

F2 · shares: Shares were sold by the Company to satisfy tax withholding obligations related to vesting of restricted stock units granted on March 6, 2023.

Read SEC document
March 07, 2025 Filed Mar 12, 2025 00:00 UTC Sarepta Therapeutics, Inc. SRPT · Entity 4426 Exercise / conversionPerformance Stock Units · Derivative 5,500 $0.00 $0.00
Disclosure

SEC source: 0000950170-25-037519 · ownership.xml · derivative · entry 5

Estepan Ian Michael · CIK 0001836254 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 5,500 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Represents the number of shares vested under a performance stock unit ("PSU") award granted to the Reporting Person on March 7, 2022. The number of shares earned was based on the Compensation Committee's determination of the Company's achievement of the milestones under the terms of the PSU.

F1 · derivative.exercise_date: Represents the number of shares vested under a performance stock unit ("PSU") award granted to the Reporting Person on March 7, 2022. The number of shares earned was based on the Compensation Committee's determination of the Company's achievement of the milestones under the terms of the PSU.

F1 · derivative.expiration_date: Represents the number of shares vested under a performance stock unit ("PSU") award granted to the Reporting Person on March 7, 2022. The number of shares earned was based on the Compensation Committee's determination of the Company's achievement of the milestones under the terms of the PSU.

Read SEC document
March 07, 2025 Filed Mar 12, 2025 00:00 UTC Sarepta Therapeutics, Inc. SRPT · Entity 4426 Exercise / conversionCommon Stock 5,500 Not disclosed Not disclosed
Disclosure

SEC source: 0000950170-25-037519 · ownership.xml · nonDerivative · entry 1

Estepan Ian Michael · CIK 0001836254 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 58,277

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Represents the number of shares vested under a performance stock unit ("PSU") award granted to the Reporting Person on March 7, 2022. The number of shares earned was based on the Compensation Committee's determination of the Company's achievement of the milestones under the terms of the PSU.

Read SEC document
March 06, 2025 Filed Mar 11, 2025 00:00 UTC Sarepta Therapeutics, Inc. SRPT · Entity 4426 Exercise / conversionPerformance Stock Units · Derivative 17,500 $0.00 $0.00
Disclosure

SEC source: 0000950170-25-036695 · ownership.xml · derivative · entry 4

Estepan Ian Michael · CIK 0001836254 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 17,500 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Represents the number of shares vested under a performance stock unit ("PSU") award granted to the Reporting Person on March 6, 2023. The number of shares earned was based on the Compensation Committee's determination of the Company's achievement of the milestones under the terms of the PSU.

F1 · derivative.exercise_date: Represents the number of shares vested under a performance stock unit ("PSU") award granted to the Reporting Person on March 6, 2023. The number of shares earned was based on the Compensation Committee's determination of the Company's achievement of the milestones under the terms of the PSU.

F1 · derivative.expiration_date: Represents the number of shares vested under a performance stock unit ("PSU") award granted to the Reporting Person on March 6, 2023. The number of shares earned was based on the Compensation Committee's determination of the Company's achievement of the milestones under the terms of the PSU.

Read SEC document
March 06, 2025 Filed Mar 11, 2025 00:00 UTC Sarepta Therapeutics, Inc. SRPT · Entity 4426 Exercise / conversionCommon Stock 17,500 Not disclosed Not disclosed
Disclosure

SEC source: 0000950170-25-036695 · ownership.xml · nonDerivative · entry 1

Estepan Ian Michael · CIK 0001836254 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 62,456

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Represents the number of shares vested under a performance stock unit ("PSU") award granted to the Reporting Person on March 6, 2023. The number of shares earned was based on the Compensation Committee's determination of the Company's achievement of the milestones under the terms of the PSU.

Read SEC document
March 04, 2025 Filed Mar 7, 2025 01:00 UTC Sarepta Therapeutics, Inc. SRPT · Entity 4426 Tax withholdingCommon Stock 1,370 $101.34 $138,835.80
Disclosure

SEC source: 0000950170-25-035003 · ownership.xml · nonDerivative · entry 1

Estepan Ian Michael · CIK 0001836254 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 44,956

F1 · shares: Shares were sold by the Company to satisfy tax withholding obligations related to vesting of restricted stock units granted on March 3, 2021.

Read SEC document
March 03, 2025 Filed Mar 5, 2025 01:00 UTC Sarepta Therapeutics, Inc. SRPT · Entity 4426 Tax withholdingCommon Stock 557 $103.77 $57,799.89
Disclosure

SEC source: 0000950170-25-032760 · ownership.xml · nonDerivative · entry 1

Estepan Ian Michael · CIK 0001836254 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 46,326

F1 · shares: Shares were sold by the Company to satisfy tax withholding obligations related to vesting of restricted stock units granted on March 1, 2024.

Read SEC document
February 11, 2025 Filed Feb 14, 2025 01:00 UTC Sarepta Therapeutics, Inc. SRPT · Entity 4426 GrantPerformance Restricted Stock Units · Derivative 3,500 $0.00 $0.00
Disclosure

SEC source: 0000950170-25-020194 · ownership.xml · derivative · entry 1

Estepan Ian Michael · CIK 0001836254 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,500

Underlying: Common Stock · 3,500 shares

Expires not disclosed

F1 · derivative.exercise_price: Represents the total number of shares earned under a PSU award granted to the Reporting Person on March 6, 2023. The number of shares earned is based on the Compensation Committee's determination of the Company's achievement of the prescribed milestones under the terms of the PSU award. The earned PSUs will vest on March 6, 2025, subject to the Reporting Person continuing to provide service to the Company through such vesting date.

F1 · derivative.exercise_date: Represents the total number of shares earned under a PSU award granted to the Reporting Person on March 6, 2023. The number of shares earned is based on the Compensation Committee's determination of the Company's achievement of the prescribed milestones under the terms of the PSU award. The earned PSUs will vest on March 6, 2025, subject to the Reporting Person continuing to provide service to the Company through such vesting date.

F1 · derivative.expiration_date: Represents the total number of shares earned under a PSU award granted to the Reporting Person on March 6, 2023. The number of shares earned is based on the Compensation Committee's determination of the Company's achievement of the prescribed milestones under the terms of the PSU award. The earned PSUs will vest on March 6, 2025, subject to the Reporting Person continuing to provide service to the Company through such vesting date.

Read SEC document
January 29, 2025 Filed Feb 1, 2025 01:30 UTC Sarepta Therapeutics, Inc. SRPT · Entity 4426 Exercise / conversionStock Option (right to buy) · Derivative 1,533 $0.00 Strike: $12.00 $0.00
Disclosure

SEC source: 0000950170-25-011959 · ownership.xml · derivative · entry 5

Estepan Ian Michael · CIK 0001836254 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 1,533 shares

Expires 2025-01-30

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
January 29, 2025 Filed Feb 1, 2025 01:30 UTC Sarepta Therapeutics, Inc. SRPT · Entity 4426 Exercise / conversionStock Option (right to buy) · Derivative 14,267 $0.00 Strike: $12.00 $0.00
Disclosure

SEC source: 0000950170-25-011959 · ownership.xml · derivative · entry 4

Estepan Ian Michael · CIK 0001836254 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 14,267 shares

Expires 2025-01-30

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
January 29, 2025 Filed Feb 1, 2025 01:30 UTC Sarepta Therapeutics, Inc. SRPT · Entity 4426 Tax withholdingCommon Stock 2,613 $117.51 $307,053.63
Disclosure

SEC source: 0000950170-25-011959 · ownership.xml · nonDerivative · entry 3

Estepan Ian Michael · CIK 0001836254 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 46,883

F1 · kind: Represents shares withheld by the Issuer to satisfy tax witholding obligations and payment by the Reporting Person of the option exercise price. The Reporting Person holds the exercised shares not withheld by the Issuer.

Read SEC document
January 29, 2025 Filed Feb 1, 2025 01:30 UTC Sarepta Therapeutics, Inc. SRPT · Entity 4426 Exercise / conversionCommon Stock 1,533 $12.00 $18,396.00
Disclosure

SEC source: 0000950170-25-011959 · ownership.xml · nonDerivative · entry 2

Estepan Ian Michael · CIK 0001836254 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 49,496

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
January 29, 2025 Filed Feb 1, 2025 01:30 UTC Sarepta Therapeutics, Inc. SRPT · Entity 4426 Exercise / conversionCommon Stock 14,267 $12.00 $171,204.00
Disclosure

SEC source: 0000950170-25-011959 · ownership.xml · nonDerivative · entry 1

Estepan Ian Michael · CIK 0001836254 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 47,963

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
December 27, 2024 Filed Dec 31, 2024 01:00 UTC Sarepta Therapeutics, Inc. SRPT · Entity 4426 GiftCommon Stock 250 $0.00 $0.00
Disclosure

SEC source: 0000950170-24-141250 · ownership.xml · nonDerivative · entry 1

Estepan Ian Michael · CIK 0001836254 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 33,696

F1 · price: Represents a charitable donation.

Read SEC document
August 30, 2024 Filed Sep 4, 2024 00:00 UTC Sarepta Therapeutics, Inc. SRPT · Entity 4426 SaleCommon Stock 5,985 $137.36 $822,099.60
Disclosure

SEC source: 0000950170-24-103070 · ownership.xml · nonDerivative · entry 1

Estepan Ian Michael · CIK 0001836254 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 33,946

F1 · shares: Represents a sale of shares of common stock to generate cash for the payment of taxes due as a result of the vesting of certain restricted stock unit awards and other compensation.

Read SEC document
June 24, 2024 Filed Jun 26, 2024 00:00 UTC Sarepta Therapeutics, Inc. SRPT · Entity 4426 Tax withholdingCommon Stock 2,483 $164.64 $408,801.12
Disclosure

SEC source: 0000950170-24-077519 · ownership.xml · nonDerivative · entry 2

Estepan Ian Michael · CIK 0001836254 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 39,931

F2 · shares: Shares were sold by the Company to satisfy tax withholding obligations related to vesting of PSUs granted on March 1, 2024.

Read SEC document
June 21, 2024 Filed Jun 26, 2024 00:00 UTC Sarepta Therapeutics, Inc. SRPT · Entity 4426 Exercise / conversionPerformance Stock Units · Derivative 6,250 $0.00 $0.00
Disclosure

SEC source: 0000950170-24-077519 · ownership.xml · derivative · entry 5

Estepan Ian Michael · CIK 0001836254 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 6,250 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Represents the number of shares earned and vested under a performance stock unit ("PSU") award granted to the Reporting Person on March 1, 2024. The number of shares earned is based on the Compensation Committee's determination of the Company's achievement of one of the prescribed milestones under the terms of the PSU. The PSUs vested immediately upon the Compensation Committee's determination of the Company's achievement of one of the prescribed milestones under the terms of the PSU.

F1 · derivative.exercise_date: Represents the number of shares earned and vested under a performance stock unit ("PSU") award granted to the Reporting Person on March 1, 2024. The number of shares earned is based on the Compensation Committee's determination of the Company's achievement of one of the prescribed milestones under the terms of the PSU. The PSUs vested immediately upon the Compensation Committee's determination of the Company's achievement of one of the prescribed milestones under the terms of the PSU.

F1 · derivative.expiration_date: Represents the number of shares earned and vested under a performance stock unit ("PSU") award granted to the Reporting Person on March 1, 2024. The number of shares earned is based on the Compensation Committee's determination of the Company's achievement of one of the prescribed milestones under the terms of the PSU. The PSUs vested immediately upon the Compensation Committee's determination of the Company's achievement of one of the prescribed milestones under the terms of the PSU.

Read SEC document
June 21, 2024 Filed Jun 26, 2024 00:00 UTC Sarepta Therapeutics, Inc. SRPT · Entity 4426 GrantPerformance Stock Units · Derivative 6,250 $0.00 $0.00
Disclosure

SEC source: 0000950170-24-077519 · ownership.xml · derivative · entry 4

Estepan Ian Michael · CIK 0001836254 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,250

Underlying: Common Stock · 6,250 shares

Expires not disclosed

F1 · derivative.exercise_price: Represents the number of shares earned and vested under a performance stock unit ("PSU") award granted to the Reporting Person on March 1, 2024. The number of shares earned is based on the Compensation Committee's determination of the Company's achievement of one of the prescribed milestones under the terms of the PSU. The PSUs vested immediately upon the Compensation Committee's determination of the Company's achievement of one of the prescribed milestones under the terms of the PSU.

F1 · derivative.exercise_date: Represents the number of shares earned and vested under a performance stock unit ("PSU") award granted to the Reporting Person on March 1, 2024. The number of shares earned is based on the Compensation Committee's determination of the Company's achievement of one of the prescribed milestones under the terms of the PSU. The PSUs vested immediately upon the Compensation Committee's determination of the Company's achievement of one of the prescribed milestones under the terms of the PSU.

F1 · derivative.expiration_date: Represents the number of shares earned and vested under a performance stock unit ("PSU") award granted to the Reporting Person on March 1, 2024. The number of shares earned is based on the Compensation Committee's determination of the Company's achievement of one of the prescribed milestones under the terms of the PSU. The PSUs vested immediately upon the Compensation Committee's determination of the Company's achievement of one of the prescribed milestones under the terms of the PSU.

Read SEC document
June 21, 2024 Filed Jun 26, 2024 00:00 UTC Sarepta Therapeutics, Inc. SRPT · Entity 4426 GrantPerformance Stock Units · Derivative 5,500 $0.00 $0.00
Disclosure

SEC source: 0000950170-24-077519 · ownership.xml · derivative · entry 3

Estepan Ian Michael · CIK 0001836254 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,500

Underlying: Common Stock · 5,500 shares

Expires not disclosed

F3 · derivative.exercise_price: Represents the number of shares earned under a PSU award granted to the Reporting Person on March 7, 2022. The number of shares earned is based on the Compensation Committee's determination of the Company's achievement of prescribed milestones under the terms of the PSU award. The earned PSUs will vest on March 7, 2025, subject to the Reporting Person continuing to provide service to the Company through such vesting date.

F3 · derivative.exercise_date: Represents the number of shares earned under a PSU award granted to the Reporting Person on March 7, 2022. The number of shares earned is based on the Compensation Committee's determination of the Company's achievement of prescribed milestones under the terms of the PSU award. The earned PSUs will vest on March 7, 2025, subject to the Reporting Person continuing to provide service to the Company through such vesting date.

F3 · derivative.expiration_date: Represents the number of shares earned under a PSU award granted to the Reporting Person on March 7, 2022. The number of shares earned is based on the Compensation Committee's determination of the Company's achievement of prescribed milestones under the terms of the PSU award. The earned PSUs will vest on March 7, 2025, subject to the Reporting Person continuing to provide service to the Company through such vesting date.

Read SEC document
June 21, 2024 Filed Jun 26, 2024 00:00 UTC Sarepta Therapeutics, Inc. SRPT · Entity 4426 Exercise / conversionCommon Stock 6,250 Not disclosed Not disclosed
Disclosure

SEC source: 0000950170-24-077519 · ownership.xml · nonDerivative · entry 1

Estepan Ian Michael · CIK 0001836254 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 42,414

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Represents the number of shares earned and vested under a performance stock unit ("PSU") award granted to the Reporting Person on March 1, 2024. The number of shares earned is based on the Compensation Committee's determination of the Company's achievement of one of the prescribed milestones under the terms of the PSU. The PSUs vested immediately upon the Compensation Committee's determination of the Company's achievement of one of the prescribed milestones under the terms of the PSU.

Read SEC document
March 08, 2024 Filed Mar 12, 2024 00:00 UTC Sarepta Therapeutics, Inc. SRPT · Entity 4426 Tax withholdingCommon Stock 1,035 $123.14 $127,449.90
Disclosure

SEC source: 0000950170-24-029529 · ownership.xml · nonDerivative · entry 2

Estepan Ian Michael · CIK 0001836254 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 36,164

F2 · shares: Shares were sold by the Company to satisfy tax withholding obligations related to vesting of restricted stock units granted on March 7, 2022.

Read SEC document
March 07, 2024 Filed Mar 12, 2024 00:00 UTC Sarepta Therapeutics, Inc. SRPT · Entity 4426 Tax withholdingCommon Stock 526 $120.49 $63,377.74
Disclosure

SEC source: 0000950170-24-029529 · ownership.xml · nonDerivative · entry 1

Estepan Ian Michael · CIK 0001836254 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 37,199

F1 · shares: Shares were sold by the Company to satisfy tax withholding obligations related to vesting of restricted stock units granted on March 6, 2023.

Read SEC document
March 04, 2024 Filed Mar 7, 2024 01:00 UTC Sarepta Therapeutics, Inc. SRPT · Entity 4426 Tax withholdingCommon Stock 1,389 $125.32 $174,069.48
Disclosure

SEC source: 0000950170-24-027498 · ownership.xml · nonDerivative · entry 1

Estepan Ian Michael · CIK 0001836254 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 37,725

F1 · shares: Shares were sold by the Company to satisfy tax withholding obligations related to vesting of restricted stock units granted on March 3, 2021.

Read SEC document
March 01, 2024 Filed Mar 6, 2024 01:00 UTC Sarepta Therapeutics, Inc. SRPT · Entity 4426 GrantStock Option (right to buy) · Derivative 12,500 $0.00 Strike: $128.67 $0.00
Disclosure

SEC source: 0000950170-24-026605 · ownership.xml · derivative · entry 4

Estepan Ian Michael · CIK 0001836254 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,500

Underlying: Common Stock · 12,500 shares

Expires 2034-03-01

F4 · derivative.exercise_date: Represents the date upon which the first 25% of the option granted vests. 1/48th of the total granted option vests and become exercisable on each monthly anniversary thereafter.

Read SEC document
March 01, 2024 Filed Mar 6, 2024 01:00 UTC Sarepta Therapeutics, Inc. SRPT · Entity 4426 SaleCommon Stock 1,200 $128.30 $153,960.00
Disclosure

SEC source: 0000950170-24-026605 · ownership.xml · nonDerivative · entry 3

Estepan Ian Michael · CIK 0001836254 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 39,114

F3 · shares: Represents a sale of shares of common stock to generate cash for the payment of taxes due as a result of the vesting of certain restricted stock unit awards.

Read SEC document
March 01, 2024 Filed Mar 6, 2024 01:00 UTC Sarepta Therapeutics, Inc. SRPT · Entity 4426 GrantCommon Stock 6,000 $0.00 $0.00
Disclosure

SEC source: 0000950170-24-026605 · ownership.xml · nonDerivative · entry 2

Estepan Ian Michael · CIK 0001836254 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 40,314

F2 · price: The Reporting Person was granted restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock. 25% of the shares of common stock underlying each RSU will vest on the first anniversary of the grant date, and additional 25% will vest on each anniversary of the Grant Date thereafter, such that the RSUs will be fully vested on the fourth anniversary of the grant date.

Read SEC document
March 01, 2024 Filed Mar 6, 2024 01:00 UTC Sarepta Therapeutics, Inc. SRPT · Entity 4426 Tax withholdingCommon Stock 365 $126.19 $46,059.35
Disclosure

SEC source: 0000950170-24-026605 · ownership.xml · nonDerivative · entry 1

Estepan Ian Michael · CIK 0001836254 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 34,314

F1 · shares: Shares were sold by the Company to satisfy tax withholding obligations related to vesting of restricted stock units granted on February 28, 2020.

Read SEC document
March 08, 2023 Filed Mar 11, 2023 01:00 UTC Sarepta Therapeutics, Inc. SRPT · Entity 4426 Tax withholdingCommon Stock 744 $153.19 $113,973.36
Disclosure

SEC source: 0001209191-23-018020 · doc4.xml · nonDerivative · entry 1

Estepan Ian Michael · CIK 0001836254 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 34,679

F1 · shares: Shares were withheld by the Company to satisfy tax withholding obligations related to vesting of restricted stock units granted on March 7, 2022.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.